Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.

European journal of clinical pharmacology - 1 May 2020

Meng Huan-Yu, Li Xi, Jin Wan-Lin, Yan Cheng-Kai, Dong Xiao-Hua, Xu Qiu, Peng Yu-Yao, Li Zhi-Bin, Li Yi, Luo Zhao-Hui, Xu Li-Qun, Yang Huan

Abstract excerpt

PURPOSE: Tacrolimus is a novel effective immunosuppressant for myasthenia gravis (MG) patients. However, the narrow therapeutic window, and high inter- and intrapatient variation in bioavailability largely limited its clinical application. This article intended to find the SNPs influencing clinical outcome and discover the possible mechanisms. METHODS: Based on the tagSNPs genotyped by Improved Multiple Ligase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asian People
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to MicroRNAs

Share to Myasthenia Gravis

Share to NFATC Transcription Factors

Share to Tacrolimus

Share to Tacrolimus Binding Proteins

Source

Identifiers

PMID: 31955224
DOI: 10.1007/s00228-019-02803-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.PMID 31955224Read ↗

Population Pharmacokinetics and Dose Optimization of Tacrolimus in Chinese Adult Patients with Myasthenia GravisSemantic proximity Read ↗

Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.Semantic proximity Read ↗

HLA-A*11:01 and HLA-C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups.Semantic proximity Read ↗

A Machine Learning-Based Identification of Genes Affecting the Pharmacokinetics of Tacrolimus Using the DMETTM Plus Platform.Semantic proximity Read ↗

Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients.Semantic proximity Read ↗

A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform.Semantic proximity Read ↗

Tacrolimus personalized therapy based on CYP3A5 genotype in Chinese patients with idiopathic inflammatory myopathies.Semantic proximity Read ↗

Trans-eQTLs of the CYP3A4 and CYP3A5 associated with tacrolimus trough blood concentration in Chinese renal transplant patients.Semantic proximity Read ↗

Genomewide association study identifies a novel variant associated with tacrolimus trough concentration in Chinese renal transplant recipients.Semantic proximity Read ↗

Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases.Semantic proximity Read ↗

Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients.Semantic proximity Read ↗

FKBP-CaN-NFAT pathway polymorphisms selected by in silico biological function prediction are associated with tacrolimus efficacy in renal transplant patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.